Natera (NTRA) Stock Trades At A Premium To Sales After A 425% Return
Natera stock has delivered a very large 424.8% return over the past three years, yet the company currently screens as expensive on several valuation checks. With the recent share price strength in focus, investors are weighing those past gains against what the current pricing implies for the road ahead.
- Over the last three years Natera has returned 424.8%, which sets a high bar for what the current valuation needs to justify.
- The growing clinical role of its Signatera test, including the recent JAMA Dermatology study in Merkel cell carcinoma, may support expectations for further adoption, while any change in clinical guidelines or competitive pressure may weigh on how much investors are willing to pay for that growth.
- Natera passes only 2 of 6 valuation checks, which points to a stock that currently appears expensive rather than a clear bargain on the broader measures.
The issue now is whether Natera's current share price offers enough compensation for the risks that come with a stock that has already risen significantly and does not screen as cheap on most valuation tests.
Is Natera Getting Expensive on Sales?
For Natera, a P/S multiple is useful because the business is still working toward consistent profitability, so investors often focus on revenue rather than earnings. Right now the stock trades on a P/S of about 15.3x, which is well above the biotech industry average of roughly 10.5x and also higher than the peer group average of about 10.5x.
The fair P/S ratio implied by Simply Wall St's model is about 9.7x, which is lower than both the current multiple and the broader peer benchmark. That suggests the market is assigning a sizeable premium to Natera compared with what this framework would expect given its growth profile, margins and risk. The recent JAMA Dermatology data and guideline support for Signatera help explain why investors are willing to pay more, but the current P/S still sits well above the level that would align with the model's fair value range.
On the P/S multiple, Natera stock currently screens as overvalued compared with both its fair ratio and biotech peers.
See what the numbers say about this price — find out in our valuation breakdown.
The Natera Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Natera pick up where this valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price, based on independent views shared on the Community page. Each one presents Natera's fair value as a specific thesis about the business that you can follow over time, rather than a one off snapshot.
Community views on Natera sit far apart, with one side focused on clinical and AI upside and the other on regulatory and cost pressure.
Bull case: 5% undervalued
"Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion…"
Read the full Bull Case to see why Natera could be undervalued
Bear case: 29% overvalued
"Broad-based healthcare cost containment initiatives by payers and governments are poised to drive down reimbursement rates and average selling prices for advanced diagnostics and non-essential screenings, directly pressuring Natera's top-line growth and compressing gross margins for years to come…"
Read the full Bear Case to see why Natera could be overvalued
Do you think there's more to the story for Natera? Head over to our Community to see what others are saying!
The Bottom Line
Natera now trades on valuation multiples that screen as overvalued on broad checks, which means the market is already pricing in a lot of good news around growth and execution. With that kind of premium, the key question is whether revenue growth, reimbursement and margins can support today’s expectations rather than just justify past enthusiasm. For many investors, the crux is whether Natera can keep expanding clinical adoption and protect pricing enough to grow into its current multiple, or whether the stock settles back if those assumptions soften.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com